NeuroMetrix has commercially launched its new DPNCheck 2.0 point-of-care device for detecting peripheral neuropathy.
The new quick, accurate, quantitative test uses nerve conduction technology to detect peripheral neuropathy, the systemic degeneration of peripheral nerves.
It offers rapid patient screening through quantitative peripheral nerve function measurement.
DPNCheck can be used to assess systemic neuropathies that include diabetic peripheral neuropathy (DPN).
It is intended for point-of-care use by clinicians to accurately detect, stage and monitor peripheral neuropathies.
The device includes step-by-step onboarding instructions, a real-time nerve response display, an easy-to-use touchscreen, improved temperature compensation and other enhancements.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Furthermore, DPNCheck’s companion software enables clinical documentation of test results.
The company is planning cloud-based population-health data aggregation as well as integration with provider electronic health record (EHR) systems later in the year.
NeuroMetrix CEO Shai Gozani said: “For more than a decade, our first-generation DPNCheck device has been used and trusted by thousands of providers to assess over two-million patients.
“We are excited to launch our newest version to even better address the needs of our clinical partners.
“We’ve opened the door to more widespread screening with a user-friendly design that makes it faster and easier for care organisations to roll out and train their point-of-care staff and deploy testing.”
The company stated that its new nerve conduction test enables the potential uncovering of elevated risk for peripheral neuropathy complications.
This allows such complications to be identified earlier and more accurately compared to traditional clinical methods, which include the monofilament and tuning fork tests.